Adverse events
immune‐related adverse, TRAEs
ADVERSE EVENTS, REACTIVE CUTANEOUS CAPILLARY ENDOTHELIAL PROLIFERATION
All 43 enrolled patients received the study drugs and were included for safety analysis. Of these, 36 patients (83.7%) completed three cycles of neoadjuvant therapy. TRAEs of any grade were reported in 95.3% of patients. Grade 3 or 4 TRAEs were reported in 34.9% of patients (Supplementary Table Treatment‐related adverse events occurring in at least 10% of patients (Abbreviation: ALC, absolute lymphocyte count; ALT, alanine transaminase; ANC, absolute neutrophil count; AST, Aspartate transaminase; irAE, immune‐related adverse event; RCCEP, reactive cutaneous capillary endothelial proliferation; WBC, white blood cell count.